Improvement of Bacterial Vaginosis and Vulvovaginal Candidiasis with a New Lactobacillus Strains Association: A Pilot Study

A clinical trial demonstrated that a vaginal composition containing specific Lactobacillus strains effectively treated these infections, with higher success rates in recurrent cases.

Bacterial vaginosis and vulvovaginal candidiasis are bacterial infections widely spread among women in childbearing age. These infections are associated with altered or disturbed vaginal microbiota, in a condition defined as vaginal dysbiosis. Restoration of the lactobacilli flora seems a promising strategy for the treatment of these pathologies. The efficacy and safety of a new vaginal composition, containing three Lactobacillus strains selected for their activity against urogenital pathogens, was assessed in a pilot clinical trial for the treatment of bacterial vaginosis and vaginal candidiasis. The study involved women with a diagnosis of bacterial vaginosis (30) or vulvovaginal candidiasis (24).

Vaginal capsules, containing the three Lactobacillus strains, were administered following one application per day for ten consecutive days. Patients received gynecological examinations before and after treatment, with objective examination, assessment of clinical symptoms severity, and vaginal wet mount microscopy. The treatment showed complete resolution in 60% of bacterial vaginosis cases and around 40% in vulvovaginal candidiasis cases. Further analyzing the subgroup characterized by recurrent vaginal candidiasis, the success rate was significantly higher than in the acute cases, showing a stronger effect of the product against persistent and chronic conditions. The product showed a resolution of the vaginal dysbiosis through vaginal wet mount examination, and no adverse effects were reported. In conclusion, the presented clinical data support the use of the Lactobacillus vaginal composition for the treatment of bacterial vaginosis and vulvovaginal candidiasis

Follow us on social media to make sure you don’t miss the next articles!

Subscribe to the newsletter and receive the complete Publication now!

    Born in 2022 as a spin-off of ROELMI HPC, we aim at becoming a leader in biotechnology thanks to all expertise gained in these years, with a huge number of projects fulfilled at worldwide level as well as the network of researchers, contributing to a multi-faced scientific approach.

    Latest Publications